We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Chronic Graft Versus Host Disease

News List

Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease PharmaSources.com
February 01, 2021
DUBLIN – January 27, 2021 – Mallinckrodt plc, a global biopharmaceutical company, announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system.
FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease drugs.com
August 03, 2017
The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. This is the first FDA-approved therapy f